EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017

  • ID: 4091065
  • Report
  • March 2017
  • 88 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acacia Pharma Ltd
  • Astellas Pharma Inc
  • Heron Therapeutics Inc
  • Kyowa Hakko Kirin Co Ltd
  • Medlab Clinical Ltd
  • RedHill Biopharma Ltd
  • MORE
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 4, 2, 1, 9, 2 and 1 respectively.

Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acacia Pharma Ltd
  • Astellas Pharma Inc
  • Heron Therapeutics Inc
  • Kyowa Hakko Kirin Co Ltd
  • Medlab Clinical Ltd
  • RedHill Biopharma Ltd
  • MORE
Introduction

Chemotherapy Induced Nausea and Vomiting - Overview

Chemotherapy Induced Nausea and Vomiting - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development

Acacia Pharma Ltd

Aphios Corp

Astellas Pharma Inc

Camurus AB

Daewoong Pharmaceutical Co Ltd

Heron Therapeutics Inc

INSYS Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

MannKind Corp

Medlab Clinical Ltd

Nemus Bioscience Inc

RedHill Biopharma Ltd

Serina Therapeutics Inc

SoluBest Ltd

Suda Ltd

Tesaro Inc

Therapix Biosciences Ltd

Chemotherapy Induced Nausea and Vomiting - Drug Profiles

(netupitant + palonosetron hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(palonosetron hydrochloride + Pro-netupitant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APD-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cannabis CINV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FK-886 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosnetupitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPI-1504 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPI-1505 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palmidrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palonosetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rolapitant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SER-232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zindol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chemotherapy Induced Nausea and Vomiting - Dormant Projects

Chemotherapy Induced Nausea and Vomiting - Discontinued Products

Chemotherapy Induced Nausea and Vomiting - Product Development Milestones

Featured News & Press Releases

Feb 27, 2017: TESARO Receives Positive CHMP Opinion for VARUBY

Feb 23, 2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant)

Jan 12, 2017: Heron Announces Submission of CINVANTI NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA

Oct 27, 2016: Mundipharma Launches Step-change Cancer Care Medicine Akynzeo in Singapore

Sep 06, 2016: TESARO to present data on Rolapitant at the 2016 European Society for Medical Oncology Annual Meeting

Jun 23, 2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer

Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing

May 18, 2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting

Apr 12, 2016: Suda Granted Canadian Patent For Sud-002 Oral Spray To Treat Nausea & Vomiting

Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency

Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration

Feb 01, 2016: Biologics Announces New Oncology Partnership

Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics Inc, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics Inc, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co Ltd, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Medlab Clinical Ltd, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience Inc, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Serina Therapeutics Inc, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro Inc, H1

Chemotherapy Induced Nausea and Vomiting - Pipeline by Therapix Biosciences Ltd, H1

Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1

Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2017 (Contd..1), H1

Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H1

List of Figures:

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Top 10 Routes of Administration, H1

Number of Products by Stage and Top 10 Routes of Administration, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Acacia Pharma Ltd
  • Aphios Corp
  • Astellas Pharma Inc
  • Camurus AB
  • Daewoong Pharmaceutical Co Ltd
  • Heron Therapeutics Inc
  • INSYS Therapeutics Inc
  • Kyowa Hakko Kirin Co Ltd
  • MannKind Corp
  • Medlab Clinical Ltd
  • Nemus Bioscience Inc
  • RedHill Biopharma Ltd
  • Serina Therapeutics Inc
  • SoluBest Ltd
  • Suda Ltd
  • Tesaro Inc
  • Therapix Biosciences Ltd
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll